ClinVar Miner

Submissions for variant NM_000038.6(APC):c.423-3T>A

dbSNP: rs587782293
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000131175 SCV000186122 pathogenic Hereditary cancer-predisposing syndrome 2023-01-20 criteria provided, single submitter clinical testing The c.423-3T>A intronic pathogenic mutation results from a T to A substitution 3 nucleotides upstream from coding exon 4 in the APC gene. This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with APC-related disease (Friedl W et al. Hered Cancer Clin Pract, 2005 Sep;3:95-114; Kerr SE et al. J Mol Diagn, 2013 Jan;15:31-43; Ambry internal data). This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Rofes P et al. J Mol Diagn, 2020 12;22:1453-1468; Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Labcorp Genetics (formerly Invitae), Labcorp RCV000686573 SCV000814096 pathogenic Familial adenomatous polyposis 1 2024-12-04 criteria provided, single submitter clinical testing This sequence change falls in intron 4 of the APC gene. It does not directly change the encoded amino acid sequence of the APC protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or altered protein product. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has been observed in individuals with familial adenomatous polyposis and/or typical or attenuated FAP and individuals undergoing APC testing (PMID: 20223039, 23159591, 33011440; internal data). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 142189). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 5, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 33011440; internal data). For these reasons, this variant has been classified as Pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000131175 SCV000905871 likely pathogenic Hereditary cancer-predisposing syndrome 2023-05-10 criteria provided, single submitter clinical testing This variant causes a T to A nucleotide substitution at the -3 position of intron 4 of the APC gene. RNA studies report that this variant results in exon 5 skipping predicted to lead to a frameshift truncation (p.Arg141Serfs*8), although the amount of aberrant RNA was not quantified (PMID: 33011440). This variant is highly similar to c.423-3_423-2delAT in terms of the variant acceptor site and its predicted splicing impact, and it may be reported as this alternate cDNA variant description by external laboratories and databases. This variant has been reported in multiple individuals affected with familial adenomatous polyposis (PMID: 20223039, 30580288; External laboratory communication). It has been shown that this variant segregates with disease in multiple members of a family affected by polyposis or colorectal cancer (PMID: 30580288). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV001353717 SCV001714738 likely pathogenic not provided 2024-05-14 criteria provided, single submitter clinical testing PS3+PS4_mod
GeneDx RCV001353717 SCV001812791 likely pathogenic not provided 2022-05-11 criteria provided, single submitter clinical testing Published functional studies demonstrate skipping of exon 5 (Rofes 2020); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 28051113, 28152038, 29570743, 20223039, 23159591, 33011440, 30580288)
Myriad Genetics, Inc. RCV000686573 SCV004044648 likely pathogenic Familial adenomatous polyposis 1 2023-04-26 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. mRNA analysis has demonstrated abnormal mRNA splicing occurs [Myriad internal data]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 20223039, 23159591, 30580288, Myriad internal data].
Baylor Genetics RCV000686573 SCV004207917 likely pathogenic Familial adenomatous polyposis 1 2022-06-29 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001353717 SCV005624443 pathogenic not provided 2024-09-11 criteria provided, single submitter clinical testing The APC c.423-3T>A variant has been reported in the published literature in individuals with familial adenomatous polyposis (FAP) (PMID: 20223039 (2005), 23159591 (2013), 30580288 (2019), 33011440 (2020)). In addition, this variant has been observed to segregate with disease in individuals affected with FAP from a single family (PMID: 33011440 (2020)). Published functional studies showed that this variant results in abnormal splicing leading to skipping of exon 5 and a truncated protein (PMID: 33011440 (2020)). The frequency of this variant in the general population, 0.000 (0/67410 chromosomes) (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity due to the removal of low-quality genotypes at this site. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on APC mRNA splicing yielded inconclusive findings. Based on the available information, this variant is classified as pathogenic.
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001353717 SCV000591027 uncertain significance not provided flagged submission clinical testing The APC c.423-3T>A variant was identified in 1 of 2332 proband chromosomes (frequency: 0.0004) from German individuals or families with FAP (Friedl 2005). The variant was identified in the ClinVar database with conflicting classifications. Ambry Genetics classified it as likely pathogenic and the Mayo Clinic Testing Laboratories as of uncertain significance. The InSight Colon Cancer Database identified it 1x with no classification and it was identified in the LOVD database 2x as having splicing effect. The c.423-3T>A variant was not identified in dbSNP, NHLBI Exome Sequencing Project (Exome Variant Server), Exome Aggregation Consortium (ExAC) database, Clinvitae database, COSMIC, “Zhejiang Colon Cancer Database”, GeneInsight COGR database, MutDB or UMD. The c.423-3T>A variant is located in the 3' splice region but does not affect the invariant -1 and -2 positions. However, positions -3 and -5 to -12 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In addition 2 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% chance of the loss of the splice acceptor site, and 1 of 5 of the above programs predict a greater than 10% chance that this variant alters a cryptic splice donor site. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.